Last $41.66 USD
Change Today -2.88 / -6.47%
Volume 468.7K
CLVS On Other Exchanges
As of 1:51 PM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

clovis oncology inc (CLVS) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $93.33
52 Week Low
08/4/14 - $35.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CLOVIS ONCOLOGY INC (CLVS)

clovis oncology inc (CLVS) Related Businessweek News

No Related Businessweek News Found

clovis oncology inc (CLVS) Details

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has three clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; rucaparib, an oral inhibitor of poly polymerase that is being explored in Phase II or III clinical trials for treating ovarian cancer patients, and Phase II clinical trials for treating pancreatic cancer patients; and lucitanib, an oral inhibitor of the tyrosine kinase Phase I/IIa clinical trials for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements with Advenchen Laboratories LLC, Avila Therapeutics, Inc., and Pfizer Inc.; collaboration and license agreement with Les Laboratoires Servier; a drug discovery collaboration agreement with Array BioPharma Inc.; and a collaboration with Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

74 Employees
Last Reported Date: 02/28/14
Founded in 2009

clovis oncology inc (CLVS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $924.5K
Co-Founder, Chief Medical Officer and Executi...
Total Annual Compensation: $635.0K
Co-Founder, Chief Regulatory Officer and Exec...
Total Annual Compensation: $592.3K
Co-Founder, Chief Financial Officer, Principa...
Total Annual Compensation: $592.3K
Senior Vice President of Commercial
Total Annual Compensation: $501.4K
Compensation as of Fiscal Year 2013.

clovis oncology inc (CLVS) Key Developments

Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in FGF-aberrant Advanced Breast Cancer

Clovis Oncology announced that its Phase 2 study of lucitanib in patients with FGF-aberrant, advanced breast cancer has commenced and the first patient dosed at a U.S. study site. Lucitanib is the Company's oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 and 2 (FGFR1-2), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR -ß). The Phase 2, open-label, randomized, multi-center study will enroll approximately 160 patients with FGFR1 or 11q-amplified, advanced breast cancer. The study will further evaluate the lucitanib dosing strategy, by comparing the progression-free survival of patients receiving 10mg or 15mg daily. The study will also assess overall response rate, duration of response, safety, tolerability, and pharmacokinetics of lucitanib. This study is part of a global development program for lucitanib in breast cancer, which includes the Servier-sponsored FINESSE study of lucitanib monotherapy being conducted in Europe, Canada and Australia as well as the Servier-sponsored INES study evaluating lucitanib in combination with fulvestrant after failure of endocrine therapy. In addition, a Clovis-sponsored Phase 2 study evaluating lucitanib in patients with FGFR1-amplified, squamous non-small cell lung cancer is scheduled to begin shortly.

Clovis Oncology, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 04:05 PM

Clovis Oncology, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 04:05 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Patrick J. Mahaffy, Co-Founder, Chief Executive Officer, President and Director.

Clovis Seeks Acquisitions

Clovis Oncology, Inc. (NasdaqGS:CLVS) may seek acquisitions. Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of its convertible senior notes due 2021 in a private placement to qualified institutional buyers. Net proceeds from sale of securities will be used for general corporate purposes, including funding of Clovis Oncology's development programs, payments of milestones pursuant to its license agreements, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLVS:US $41.66 USD -2.88

CLVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLVS.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLVS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 110.7x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 91.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLOVIS ONCOLOGY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at